LIF LEVELS IN CORD BLOOD AND MATERNAL BLOOD DURING LABOR Clinical Trial
Official title:
The Correlation Between LIF Levels in Cord Blood to Maternal Blood in Women Treated With Mg During Labor
During embryonic development, there are several cytokines such as: LIF (Leukemia inhibitory
factor), ciliary neurotrophic factor (CNTF), epidermal growth factor family (EGF),
neuregulin 1 (NRG1) and transforming growth factor β (TGFβ) that were found are associated
with neurogenesis and differentiation of brain cells.
LIF is a cytokine that is essential for the development of the central nervous system, and
has recently been shown in rats that maternal LIF stimulates placental ACTH
(adrenocorticotropic hormone) that in turn promotes secretion of fetal LIF from nRBC
(nucleated red blood cell ), which in turn promotes brain development of the fetus In other
studies on rats a theory was proposed that LPS (lipopolysaccharide) and infection during
pregnancy influence the normal development of the brain and may cause brain damage by
altering placental ACTH thank in turn alters LIF secretion in the embryo which could be the
cause of brain damage.
Our hypothesis is that by treating the mother with Magnesium Sulphate we can protect the
embryo's brain in one of two ways:
1. Altering Placental ACTH
2. Altering the number of receptors for LIF in the brain Women who are at risk for preterm
labor prior to 32 weeks of gestation are treated with Magnesium Sulphate for
neuroprotection, randomized controlled studies showed that if these women are treated
in the 24 hours prior to labor with magnesium sulphate the risk for cerebral palsy and
other severe motor problems are decreased.
The mechanism for this decrease is unknown and that is the purpose of our study.
The purpose of our research is to examine maternal LIF levels prior to birth and Maternal
and cord levels after delivery and to see if levels are different if the mother was treated
with Magnesium Sulphate. We will also check the placental ACTH level
| Status | Not yet recruiting |
| Enrollment | 100 |
| Est. completion date | June 2017 |
| Est. primary completion date | June 2017 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Female |
| Age group | 16 Years to 45 Years |
| Eligibility |
Inclusion Criteria: 1. Women in 31-32 weeks gestation that where treated with Magnesium Sulphate for neuroprotection. 2. Women in 33-34 weeks gestation that per protocol are not entitled for treatment with Magnesium Sulphate for neuroprotection. 3. Women that had severe preeclampsia and where treated with Magnesium Sulphate for seizure prophylaxis and delivered after 34 weeks of gestation. 4. Low risk pregnancies in similar weeks to group 3 that did not require any special treatment and delivered after 34 weeks of gestation Exclusion Criteria: - Women who do not agree known genetic diseases or fetal abnormality |
Observational Model: Case Control, Time Perspective: Prospective
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Rambam Health Care Campus |
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Correlation between LIF Levels in women who where treated with Mg and women who where not (maternal LIF levels prior to birth and Maternal and cord levels after delivery) | 2 years | No |